TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17209177

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplement (600 mg elemental calcium and 200 IU vitamin D/tablet, 2 tablets/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplement
Number of subjects: 63
Study: 14987190

Group type: EXPERIMENTAL
Intervention: Graded exercise therapy programme
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study: 11193224

Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) strength training, n = 9 participants
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) strength training, n = 9 participants
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group, n = 9 participants
Number of subjects: 27
Study: 9134445

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for four months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cognitive‐based stress education control (SEC) for four months
Number of subjects: 39
Study: 8205276

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study: 3229875

Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30049691

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements using standard mercury sphygmomanometers
Number of subjects: 60025
Study: 27500660

Group type: EXPERIMENTAL
Intervention: Termination of pregnancy (TOP)
Number of subjects: 742
Study: 26168681

Group type: EXPERIMENTAL
Intervention: Rengalin (2 tablets 3 times daily for 3 days, then half dose for 4 days)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Codelac (1 tablet 3 times daily for 7 days)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Rengalin
Number of subjects: 143
Study: 23254595

Group type: EXPERIMENTAL
Intervention: Reduced-sodium, high-potassium salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Normal salt (100% sodium chloride)
Number of subjects: 462
Study: 21910897

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 4-port conventional laparoscopic cholecystectomy (4PLC)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: SPLC
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: SPLC and 4PLC
Number of subjects: 110
Study: 18381567

Group type: EXPERIMENTAL
Intervention: MC-1, 250 mg/d
Number of subjects: 3023

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3023

Group type: EXPERIMENTAL
Intervention: MC-1
Number of subjects: 3023
Study: 17064600

Group type: EXPERIMENTAL
Intervention: On-pump CABG (CCABG)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (CCABG and OPCAB)
Number of subjects: 79
Study: 12747229

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 10 mg of dexamethasone phosphate in two doses at an interval of 12 hours
Number of subjects: 66
Study: 15163329

Group type: EXPERIMENTAL
Intervention: 15 mg MMI
Number of subjects: 30

Group type: COMPARATOR
Intervention: 150 mg PTU
Number of subjects: 30
Study: 9922408

Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture (heliox)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 205
Study: 8549882

Group type: EXPERIMENTAL
Intervention: Ceruletid (1.5 micrograms/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 2109658

Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 346153

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (antifibrinolytic agent) for six weeks after rupture of an intracranial aneurysm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic treatment)
Number of subjects: 50
Study: 31304912

Group type: EXPERIMENTAL
Intervention: Anaesthetic-analgesic ear drops
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo ear drops
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Active drops (three-group study)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Economic analysis of NHS costs for active drops
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 106
Study: 28229980

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral iron supplementation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation with acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-acupuncture combined with oral iron supplementation
Number of subjects: 60
Study: 25855340

Group type: COMPARATOR
Intervention: Liraglutide 0.6 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Liraglutide 1.2 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 45
Study: 23807360

Group type: EXPERIMENTAL
Intervention: Human RV vaccine (RIX4414)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 21849007

Group type: EXPERIMENTAL
Intervention: Sitagliptin (SITA) 100 mg qd
Number of subjects: 492

Group type: COMPARATOR
Intervention: Pioglitazone (PIO) 15 mg qd (up-titrated to 30 mg after 6 weeks)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin (SITA/MET) (up-titrated to 50/1000 mg bid over 4 weeks)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Pioglitazone (PIO) (up-titrated to 45 mg qd)
Number of subjects: 492
Study: 19892280

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.50%
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.75%
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (1100 ppm F, NaF)
Number of subjects: 81
Study: 16860258

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 5924

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 5924

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 5924

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 5924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5924
Study: 15005812

Group type: EXPERIMENTAL
Intervention: Psyllium-based supplement (1 tablespoon with 8 oz of water, twice daily for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11355932

Group type: EXPERIMENTAL
Intervention: Blocking P‐glycoprotein‐mediated drug efflux
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDR1, MRP1 and LRP expression
Number of subjects: 0
Study: 9160925

Group type: EXPERIMENTAL
Intervention: 40 microg ipratropium bromide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 microg ipratropium bromide
Number of subjects: 0
Study: 7714551

Group type: EXPERIMENTAL
Intervention: PCNU 75-100 mg/m2 IV every 8 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: AZQ 15 mg/m2 IV once a week for 4 weeks, every 6-8 weeks
Number of subjects: 152
Study: 30241126

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 1
Study: 27921414

Group type: EXPERIMENTAL
Intervention: Autologous serum therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 23914845

Group type: EXPERIMENTAL
Intervention: Concussed subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 24353020

Group type: EXPERIMENTAL
Intervention: Red morphine drops (RMD) - 1/12 of their 24-hour morphine dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (SCM) - 60 percent of their 24-hour morphine dose
Number of subjects: 20
Study: 20950405

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 51
Study: 17645558

Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen A (4 mg/4 mg OD maximal)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen B (8 mg/4 mg OD maximal)
Number of subjects: 901

Group type: COMPARATOR
Intervention: RSG (8 mg OD maximal)
Number of subjects: 901

Group type: COMPARATOR
Intervention: GLIM (4 mg OD maximal)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen A
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen B
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC
Number of subjects: 901
Study: 16710084

Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 10
Study: 12800456

Group type: EXPERIMENTAL
Intervention: Standard doxazosin
Number of subjects: 1705

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS formulation
Number of subjects: 1705
Study: 11203858

Group type: EXPERIMENTAL
Intervention: Variolink Low (Vivadent; n = 18)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tetric (n = 21; Vivadent)
Number of subjects: 16
Study: 8841156

Group type: EXPERIMENTAL
Intervention: Vancomycin therapeutic drug monitoring (TDM) group (n = 37)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vancomycin therapeutic drug monitoring (TDM)
Number of subjects: 70
Study: 1478400

Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg) followed by Molsidomine (4 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 40
Study: 2858145

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg and Vecuronium 0.005 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg and Vecuronium 0.01 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg and Vecuronium 0.015 mg/kg
Number of subjects: 24
Study: 29571083

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) chemotherapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 195
Study: 25909598

Group type: EXPERIMENTAL
Intervention: Prebiotic (fructo-oligosaccharide, FOS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Synbiotic (FOS+Lactobacillus and Bifidobacteria strains)
Number of subjects: 18
Study: 25132158

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (50 mg.kg(‐1) followed by a continuous infusion of 15 mg.kg(‐1) .h(‐1))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isotonic saline (same volume as magnesium group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 44
Study: 22584952

Group type: EXPERIMENTAL
Intervention: 200 g of chocolate containing 80% cacao
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cacao-free white chocolate (placebo)
Number of subjects: 26
Study: 20432513

Group type: EXPERIMENTAL
Intervention: Applied Tension (AT) technique
Number of subjects: 614

Group type: COMPARATOR
Intervention: No treatment (donation-as-usual condition)
Number of subjects: 614
Study: 18584274

Group type: EXPERIMENTAL
Intervention: Feedback on colonoscopy performance
Number of subjects: 581

Group type: COMPARATOR
Intervention: No feedback on colonoscopy performance
Number of subjects: 581
Study: 16133430

Group type: COMPARATOR
Intervention: Healthy voluntary subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with swallowing disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with tracheal tubes or cannulae
Number of subjects: 0
Study: 12182385

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine (HbOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children excluded from the trial)
Number of subjects: 0
Study: 10201676

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 340

Group type: COMPARATOR
Intervention: 2% mepivacaine
Number of subjects: 340
Study: 7801861

Group type: EXPERIMENTAL
Intervention: Colestipol 10 g and lovastatin 20 mg/day (C10 + L20)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Colestipol 5 g and lovastatin 20 mg/day (C5 + L20)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lovastatin 40 mg/day (L40)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose combinations
Number of subjects: 96
Study: 2139940

Group type: EXPERIMENTAL
Intervention: imipenem-cilastatin 500 mg 8-hourly
Number of subjects: 211

Group type: COMPARATOR
Intervention: cefotaxime 1 g 6-hourly combined with amikacin 5 mg/kg 8-hourly
Number of subjects: 211
Study: 378733

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 100 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Phenylpropanolamine 50 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31247584

Group type: EXPERIMENTAL
Intervention: V-K group (focused first on visual information, then on kinesthetic information)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: K-V group (focused first on kinesthetic information, then on visual information)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Random group (randomly shifted focus between visual and kinesthetic information)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bi-modal training (combined visual and kinesthetic information)
Number of subjects: 30
Study: 29561515

Group type: EXPERIMENTAL
Intervention: Lidocaine (0.2-0.4 mg/kg) coadministered with amikacin (15 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amikacin (15 mg/kg) without lidocaine
Number of subjects: 12
Study: 27803922

Group type: EXPERIMENTAL
Intervention: Single Bond Universal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intact control group
Number of subjects: 28
Study: 25454409

Group type: EXPERIMENTAL
Intervention: 3-item craving scale administered weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Craving assessment including urges, cue-induced craving, and perceived likelihood of relapse
Number of subjects: 0
Study: 22702067

Group type: EXPERIMENTAL
Intervention: GnRH analogues pre-treatment before laparoscopic myomectomy (LM)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: GnRH analogues pre-treatment before open laparotomic myomectomy (OM)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no pre-treatment) for laparoscopic myomectomy (LM)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no application) for open laparotomic myomectomy (OM)
Number of subjects: 212
Study: 20580216

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 microg twice-daily plus Tiotropium 18 microg once-daily (FOR-TIO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Formoterol fumarate 12 microg twice-daily plus placebo (FOR-PLA)
Number of subjects: 33
Study: 17854302

Group type: EXPERIMENTAL
Intervention: Patients with β-thalassaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with sickle cell anaemia (SCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal phospholipid membrane asymmetry in red blood cells
Number of subjects: 0
Study: 16223967

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 12812432

Group type: EXPERIMENTAL
Intervention: Intra-investigator measurements using contour ROI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-investigator measurements using contour ROI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All ROIs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contour ROI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 30
Study: 10327085

Group type: EXPERIMENTAL
Intervention: 20 cm viewing distance
Number of subjects: 24

Group type: COMPARATOR
Intervention: 60 cm viewing distance
Number of subjects: 24
Study: 9121622

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) as add‐on therapy to standard antidepressive medication
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard antidepressive medication only
Number of subjects: 24
Study: 1707797

Group type: EXPERIMENTAL
Intervention: Instruction to refrain from blinking
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instruction to refrain from blinking (Control)
Number of subjects: 0
Study: 7117166

Group type: EXPERIMENTAL
Intervention: 20 mg of 5‐isosorbide mononitrate (5‐ISMN)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 50 mg of 5‐isosorbide mononitrate (5‐ISMN)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 50 mg of 5‐isosorbide mononitrate (5‐ISMN) three times daily for four weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chronic administration of high doses of 5‐ISMN
Number of subjects: 31
Study: 29808615

Group type: EXPERIMENTAL
Intervention: Objective image-scoring system for pulsed-wave Doppler measurement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subjective assessment of Doppler images
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Objective scoring system components
Number of subjects: 120
Study: 28509813

Group type: EXPERIMENTAL
Intervention: Fennel (100 mg, 2 capsules per day for 8 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (2 capsules per day for 8 weeks)
Number of subjects: 90
Study: 25975205

Group type: EXPERIMENTAL
Intervention: Variable dose warfarin (target INR 2.0-2.5), treated for 28 ± 2 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fixed low-dose warfarin (1 mg daily starting 7 days preoperatively), treated for 28 ± 2 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin (325 mg daily starting on the day of surgery), treated for 28 ± 2 days
Number of subjects: 36
Study: 24190687

Group type: EXPERIMENTAL
Intervention: Guided strength training program (twice weekly for 19 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Physical education classes
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Guided strength training program
Number of subjects: 102
Study: 21285171

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg eow
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg weekly
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Adalimumab (combined data)
Number of subjects: 457
Study: 19685072

Group type: EXPERIMENTAL
Intervention: Incremental exercise to determine peak oxygen consumption (V(O)(2peak))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Steady state exercise at 50% of V(O)(2peak)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Steady state exercise at 60% of V(O)(2peak)
Number of subjects: 18
Study: 18024668

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 15156251

Group type: EXPERIMENTAL
Intervention: Topical Aescin + essential phospholipids (AEPL) gel applied for 2 weeks, three times daily
Number of subjects: 10
Study: 10802843

Group type: EXPERIMENTAL
Intervention: Light smoking
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Heavy smoking
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 1146
Study: 8873362

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: General anesthesia (control)
Number of subjects: 22
Study: 2060547

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.d.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6227781

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study: 30715153

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (second course)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study: 29378603

Group type: EXPERIMENTAL
Intervention: Additional radiotherapy (RT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-radiotherapy (non-RT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Chemotherapy following ESD
Number of subjects: 27

Group type: COMPARATOR
Intervention: Overall survival and cause-specific survival
Number of subjects: 27
Study: 26564676

Group type: EXPERIMENTAL
Intervention: Core strengthening exercises (5 exercises, 4 days/week for 12 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular exercise regimen (control group)
Number of subjects: 12
Study: 22281376

Group type: EXPERIMENTAL
Intervention: Quick-view reading mode
Number of subjects: 106

Group type: COMPARATOR
Intervention: Initial reading
Number of subjects: 106
Study: 20627022

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 1 mg/kg intravenous 15 minutes before induction of general anesthesia (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No premedication (Group A)
Number of subjects: 60
Study: 18343243

Group type: EXPERIMENTAL
Intervention: MLR methylphenidate 20 mg QD
Number of subjects: 21

Group type: COMPARATOR
Intervention: OROS methylphenidate 18 mg QD
Number of subjects: 21
Study: 15841929

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 100 microg every 2 hours
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg every 4 hours
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oral misoprostol 100 microg every 2 hours
Number of subjects: 153